BENEŠOVÁ, Yvonne. TYSABRI – nový management rizik (TYSABRI – new management of risk factors). Neurologie pro praxi. Olomouc: Solen, 2017, vol. 18, No 3, p. 202-206. ISSN 1213-1814.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name TYSABRI – nový management rizik
Name (in English) TYSABRI – new management of risk factors
Authors BENEŠOVÁ, Yvonne (203 Czech Republic, guarantor, belonging to the institution).
Edition Neurologie pro praxi, Olomouc, Solen, 2017, 1213-1814.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30210 Clinical neurology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/17:00098509
Organization unit Faculty of Medicine
Keywords in English natalizumab; monoclonal antibodies; multiple sclerosis; progressive multifocal leukoencephalopathy
Tags EL OK
Tags Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 19/3/2018 17:45.
Abstract
Natalizumab řadíme mezi selektivní monoklonální protilátky. Jedná se o velmi účinný lék, který podstatně snižuje aktivitu nemoci a vede k dlouhodobé stabilizaci roztroušené sklerózy mozkomíšní. Terapie je bohužel spojena s rizikem rozvoje progresivní multifokální leukoencefalopatie (PML) u pacientů s pozitivitou protilátek proti John Cunningham viru. Standardizované, pravidelné klinické sledování, monitorace magnetickou rezonancí a využití biomarkerů umožňuje stratifikovat riziko rozvoje PML. Včasné zjištění PML choroby v asymptomatickém stadiu podstatně zlepšuje přežití a snižuje následky tohoto onemocnění.
Abstract (in English)
Natalizumab belongs to monoclonal antibodies. This is a high- efficacy drug, which substantially reduces the activity and leads to long-term stabilization of multiple sclerosis. However, the therapy is associated with a risk of developing progressive multifocal leukoencephalopathy (PML) in patients infected with the John Cunningham Virus. Standardized high-quality monitoring procedures, clinical assessments, magnetic resonance imaging monitoring and use of biomarkers enable risk stratification. Early detection of disease in asymptomatic stage substantially improves survival and reduce the functional outcomes.
PrintDisplayed: 28/5/2024 19:25